Drug targets and predictive biomarkers in the management of metastatic melanoma

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• BalchCMGershenwaldJESoongSJFinal version of 2009 AJCC melanoma staging and classificationJ Clin Oncol200927366199620619917835
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• MiddletonMRGrobJJAaronsonNRandomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaJ Clin Oncol200018115816610623706
   PubMed Web of Science ®Google Scholar
• SznolMPowderlyDSmithDCSafety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies [abstract 2506]J Clin Oncol201028Suppl15s
   Google Scholar
• AtkinsMBKunkelLSznolMRosenbergSAHigh-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateCancer J Sci Am20006Suppl 1S11S1410685652
   PubMed Web of Science ®Google Scholar
• BesserMJTrevesAJItzhakiOAdoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical CenterIsr Med Assoc J20068316416816599050
   PubMed Web of Science ®Google Scholar
• DudleyMEYangJCSherryRAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensJ Clin Oncol200826325233523918809613
   PubMed Web of Science ®Google Scholar
• HodiFSO'DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• SznolMMolecular markers of response to treatment for melanomaCancer J201117212713321427556
   PubMed Web of Science ®Google Scholar
• HamidOTsuchihashiZAlaparthySGalbraithSBermanDAssociation of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab [abstract 9008]J Clin Oncol200927Suppl15S
   Google Scholar
• HamidOSchmidtHNissanAA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJ Transl Med2011920422123319
   PubMed Web of Science ®Google Scholar
• YuanJAdamowMGinsbergBAIntegrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabProc Natl Acad Sci U S A201110840167231672821933959
   PubMed Web of Science ®Google Scholar
• GoffSLRobbinsPFEl-GamilMRosenbergSANo correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanomaJ Immunother200932888488519752745
   PubMed Web of Science ®Google Scholar
• TarhiniAAEdingtonHButterfieldLHNeoadjuvant ipilimumab in patients with stage IIIB/C melanoma: immunogenicity and biomarker analysis [abstract 8536]J Clin Oncol201129Suppl15S
   Google Scholar
• HodiFSTissue and blood biomarkers from patients with stage iii or stage iv melanoma treated with ipilimumab with or without sargramostim Available from: http://clinicaltrials.gov/ct2/show/NCT01489423. Accessed July 14, 2012
   Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerNew Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerNew Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919122931229712218188
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurr Opin Immunol201224220721222236695
   PubMed Web of Science ®Google Scholar
• SatyamoorthyKLiGGerreroMRConstitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulationCancer Res200363475675912591721
   PubMed Web of Science ®Google Scholar
• DhawanPRichmondAA novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cellsJ Biol Chem2002277107920792811773061
   PubMed Web of Science ®Google Scholar
• LiuJSuresh KumarKGYuDOncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cellsOncogene200726131954195817001349
   PubMed Web of Science ®Google Scholar
• BroseMSVolpePFeldmanMBRAF and RAS mutations in human lung cancer and melanomaCancer Res200262236997700012460918
   PubMed Web of Science ®Google Scholar
• DhomenNMaraisRBRAF signaling and targeted therapies in melanomaHematol Oncol Clin North Am2009233529545ix19464601
   PubMed Web of Science ®Google Scholar
• RubinsteinJCSznolMPavlickACIncidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032J Transl Med201086720630094
   PubMed Web of Science ®Google Scholar
• PollockPMCohen-SolalKSoodRMelanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasiaNat Genet200334110811212704387
   PubMed Web of Science ®Google Scholar
• SharmaATrivediNRZimmermanMATuvesonDASmithCDRobertsonGPMutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumorsCancer Res20056562412242115781657
   PubMed Web of Science ®Google Scholar
• FurgeKAKiewlichDLePSuppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinaseProc Natl Acad Sci U S A20019819107221072711535809
   PubMed Web of Science ®Google Scholar
• BardeesyNKimMXuJRole of epidermal growth factor receptor signaling in RAS-driven melanomaMol Cell Biol200525104176418815870287
   PubMed Web of Science ®Google Scholar
• JakobJABassettRLJrNgCSNRAS mutation status is an independent prognostic factor in metastatic melanomaCancer Epub December 16, 2011
   Web of Science ®Google Scholar
• DevittBLiuWSalemiRClinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell Melanoma Res201124466667221615881
   PubMed Web of Science ®Google Scholar
• MonselGOrtonneNBagotMBensussanADumazNc-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytesOncogene201029222723619802003
   PubMed Web of Science ®Google Scholar
• PoynterJNElderJTFullenDRBRAF and NRAS mutations in melanoma and melanocytic neviMelanoma Res200616426727316845322
   PubMed Web of Science ®Google Scholar
• LongGVMenziesAMNagrialAMPrognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol201129101239124621343559
   PubMed Web of Science ®Google Scholar
• JosephRWSullivanRJHarrellRCorrelation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaJ Immunother2012351667222130161
   PubMed Web of Science ®Google Scholar
• Van RaamsdonkCDGriewankKGCrosbyMBMutations in GNA11 in uveal melanomaN Engl J Med2010363232191219921083380
   PubMed Web of Science ®Google Scholar
• BesaratiniaAPfeiferGPUveal melanoma and GNA11 mutations: a new piece added to the puzzlePigment Cell Melanoma Res2011241182021159145
   PubMed Web of Science ®Google Scholar
• Van RaamsdonkCDBezrookoveVGreenGFrequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature2009457722959960219078957
   PubMed Web of Science ®Google Scholar
• YardenYKuangWJYang-FengTHuman proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligandEMBO J1987611334133512448137
   PubMed Web of Science ®Google Scholar
• McNieceIKBriddellRAStem cell factorJ Leukoc Biol199558114227542304
   PubMed Web of Science ®Google Scholar
• LuxMLRubinBPBiaseTLKIT extracellular and kinase domain mutations in gastrointestinal stromal tumorsAm J Pathol2000156379179510702394
   PubMed Web of Science ®Google Scholar
• CarvajalRDAntonescuCRWolchokJDKIT as a therapeutic target in metastatic melanomaJAMA2011305222327233421642685
   PubMed Web of Science ®Google Scholar
• CurtinJABusamKPinkelDBastianBCSomatic activation of KIT in distinct subtypes of melanomaJ Clin Oncol200624264340434616908931
   PubMed Web of Science ®Google Scholar
• GarridoMCBastianBCKIT as a therapeutic target in melanomaJ Invest Dermatol20101301202719847190
   PubMed Web of Science ®Google Scholar
• TsaiJLeeJTWangWDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A200810583041304618287029
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaNew Engl J Med2010363980981920818844
   PubMed Web of Science ®Google Scholar
• SosmanJAKimKBSchuchterLSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibNew Engl J Med2012366870771422356324
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationNew Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• KeffordRArkenauHBrownMPPhase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract 8503]J Clin Oncol201028Suppl15s
   PubMed Web of Science ®Google Scholar
• SuFVirosAMilagreCRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsNew Engl J Med2012366320721522256804
   PubMed Web of Science ®Google Scholar
• HalaitHDemartinKShahSAnalytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanomaDiagn Mol Pathol20122111822306669
   PubMedGoogle Scholar
• TanYHLiuYEuKWDetection of BRAF V600E mutation by pyrosequencingPathology200840329529818428050
   PubMed Web of Science ®Google Scholar
• AndersonSBloomKJValleraDUMultisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanomaArch Pathol Lab Med Epub February 14, 2012
   Web of Science ®Google Scholar
• CapperDBerghoffASMagerleMImmunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesActa Neuropathol2012123222323322012135
   PubMed Web of Science ®Google Scholar
• AndrulisMPenzelRWeichertWvon DeimlingACapperDApplication of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemiaAm J Surg Pathol Epub April 22, 2012
   Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsNew Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• ShenSSZhangPSEtonOPrietoVGAnalysis of protein tyrosine kinase expression in melanocytic lesions by tissue arrayJ Cutan Pathol200330953954714507401
   PubMed Web of Science ®Google Scholar
• UgurelSHildenbrandRZimpferALack of clinical efficacy of imatinib in metastatic melanomaBr J Cancer20059281398140515846297
   PubMed Web of Science ®Google Scholar
• WymanKAtkinsMBPrietoVMulticenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyCancer200610692005201116565971
   PubMed Web of Science ®Google Scholar
• KimKBEtonODavisDWPhase II trial of imatinib mesylate in patients with metastatic melanomaBr J Cancer92200899573474018728664
   PubMed Web of Science ®Google Scholar
• HodiFSFriedlanderPCorlessCLMajor response to imatinib mesylate in KIT-mutated melanomaJ Clin Oncol420200826122046205118421059
   PubMed Web of Science ®Google Scholar
• LutzkyJBauerJBastianBCDose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationPigment Cell Melanoma Res8200821449249318510589
   PubMed Web of Science ®Google Scholar
• SatzgerIKuttlerUVolkerBSchenckFKappAGutzmerRAnal mucosal melanoma with KIT-activating mutation and response to imatinib therapy – case report and review of the literatureDermatology20102201778119996579
   PubMed Web of Science ®Google Scholar
• YamaguchiMHaradaKAndoNKawamuraTShibagakiNShimadaSMarked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumbClin Exp Dermatol3201136217417720545949
   PubMed Web of Science ®Google Scholar
• GuoJSiLKongYPhase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJ Clin Oncol720201129212904290921690468
   PubMed Web of Science ®Google Scholar
• ChoJHKimKMKwonMKimJHLeeJNilotinib in patients with metastatic melanoma harboring KIT gene aberrationInvest New Drugs1192011
   PubMed Web of Science ®Google Scholar
• KlugerHMDudekAZMcCannCA phase 2 trial of dasatinib in advanced melanomaCancer5152011117102202220821523734
   PubMed Web of Science ®Google Scholar
• MinorDRKashani-SabetMGarridoMO'DaySJHamidOBastianBCSunitinib therapy for melanoma patients with KIT mutationsClin Cancer Res3120121851457146322261812
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaALazarAJWoodmanSEKimKRossMHwuPComplete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenibNat Clin Pract Oncol12200851273774018936790
   PubMedGoogle Scholar
• WoodmanSETrentJCStemke-HaleKActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesMol Cancer Ther82009882079208519671763
   PubMed Web of Science ®Google Scholar
• ZhangXDBorrowJMZhangXYNguyenTHerseyPActivation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondriaOncogene515200322192869288112771938
   PubMed Web of Science ®Google Scholar
• InfanteJRNallapareddySGordonMSMessersmith. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212Paper presented at: ASCO annual meeting 2010
   Google Scholar
• DummerRChapmanPBSosmanJAAZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II studyPaper presented at: ASCO annual meeting 2008Chicago, IL, USA
   Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature12162010468732697397721107323
   PubMed Web of Science ®Google Scholar
• JohannessenCMBoehmJSKimSYCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature12162010468732696897221107320
   PubMed Web of Science ®Google Scholar
• MontagutCSharmaSVShiodaTElevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanomaCancer Research615200868124853486118559533
   PubMed Web of Science ®Google Scholar
• WangHDaoutiSLiWHIdentification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutationCancer research815201171165535554521705440
   PubMed Web of Science ®Google Scholar
• InfanteJRLawrenceDPWeberJSPhase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)Paper presented at: ASCO annual meeting 2011Chicago, IL, USA
   Google Scholar
• StahlJMSharmaACheungMDeregulated Akt3 activity promotes development of malignant melanomaCancer research101200464197002701015466193
   PubMed Web of Science ®Google Scholar
• MikhailMVelazquezEShapiroRPTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferationClinical Cancer Research: An Official Journal of the American Association for Cancer Research715200511145153515716033830
   PubMed Web of Science ®Google Scholar